Advertisement
Screener

Edwards Lifesciences Corporation (EW) Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax

2.9 / 5 stars · 70/120 Roast Me

Edwards Lifesciences Corporation Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax

Edwards Lifesciences Corporation (EW) reported Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax of $15.20 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-06.

Financial Statements › Notes

us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax · last filed 2026-05-06

  • Edwards Lifesciences Corporation reclassification from accumulated other comprehensive income, current period, before tax for the quarter ending 2026-03-31 was $15.20M, a 47.40% decline year-over-year.
  • Edwards Lifesciences Corporation reclassification from accumulated other comprehensive income, current period, before tax for the quarter ending 2025-09-30 was $15.50M, a 20.10% decline year-over-year.
  • Edwards Lifesciences Corporation reclassification from accumulated other comprehensive income, current period, before tax for the quarter ending 2025-06-30 was $31.40M, a 136.09% increase year-over-year.
  • Edwards Lifesciences Corporation reclassification from accumulated other comprehensive income, current period, before tax for the quarter ending 2025-03-31 was $28.90M, a 351.56% increase year-over-year.
  • Edwards Lifesciences Corporation reclassification from accumulated other comprehensive income, current period, before tax for fiscal 2018 was -$15.30M, a 280.00% decline from fiscal 2017.
  • Edwards Lifesciences Corporation reclassification from accumulated other comprehensive income, current period, before tax for fiscal 2017 was $8.50M, a 23.19% increase from fiscal 2016.
  • Edwards Lifesciences Corporation reclassification from accumulated other comprehensive income, current period, before tax for fiscal 2016 was $6.90M, a 89.50% decline from fiscal 2015.
  • Edwards Lifesciences Corporation reclassification from accumulated other comprehensive income, current period, before tax for fiscal 2015 was $65.70M, a 838.57% increase from fiscal 2014.
Period endReclassification from Accumulated Other Comprehensive Income, Current Period, before Tax 3 monthReclassification from Accumulated Other Comprehensive Income, Current Period, before Tax 6 monthReclassification from Accumulated Other Comprehensive Income, Current Period, before Tax 9 monthReclassification from Accumulated Other Comprehensive Income, Current Period, before Tax 12 month
2026-03-31$15.20M
10-Q · filed 2026-05-06
2025-09-30$15.50M
10-Q · filed 2025-11-05
$46.90M
derived: sum of 2 quarters · filed 2025-11-05
$75.80M
derived: sum of 3 quarters · filed 2026-05-06
2025-06-30$31.40M
10-Q · filed 2025-11-05
$60.30M
derived: sum of 2 quarters · filed 2026-05-06
2025-03-31$28.90M
10-Q · filed 2026-05-06
2024-09-30$19.40M
10-Q · filed 2025-11-05
$32.70M
derived: sum of 2 quarters · filed 2025-11-05
$39.10M
derived: sum of 3 quarters · filed 2025-11-05
2024-06-30$13.30M
10-Q · filed 2025-11-05
$19.70M
derived: sum of 2 quarters · filed 2025-11-05
2024-03-31$6.40M
10-Q · filed 2025-11-05
2019-09-30$35.70M
10-Q · filed 2019-10-25
2019-03-31$8.60M
10-Q · filed 2019-04-26
$18.10M
derived: sum of 2 quarters · filed 2019-04-26
$12.50M
derived: sum of 3 quarters · filed 2019-04-26
-$2.10M
derived: sum of 4 quarters · filed 2019-04-26
2018-12-31$9.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-15
$3.90M
derived: sum of 2 quarters · filed 2019-02-15
-$10.70M
derived: sum of 3 quarters · filed 2019-02-15
-$15.30M
10-K · filed 2019-02-15
2018-09-30-$5.60M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-26
-$20.20M
derived: sum of 2 quarters · filed 2018-10-26
-$24.80M
10-Q · filed 2018-10-26
-$22.00M
derived: sum of 4 quarters · filed 2019-02-15
2018-06-30-$14.60M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-27
-$19.20M
10-Q · filed 2018-07-27
-$16.40M
derived: sum of 3 quarters · filed 2019-02-15
-$14.80M
derived: sum of 4 quarters · filed 2019-02-15
2018-03-31-$4.60M
10-Q · filed 2018-04-27
-$1.80M
derived: sum of 2 quarters · filed 2019-02-15
-$200.00K
derived: sum of 3 quarters · filed 2019-02-15
$1.80M
derived: sum of 4 quarters · filed 2019-02-15
2017-12-31$2.80M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-15
$4.40M
derived: sum of 2 quarters · filed 2019-02-15
$6.40M
derived: sum of 3 quarters · filed 2019-02-15
$8.50M
10-K · filed 2019-02-15
2017-09-30$1.60M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-27
$3.60M
derived: sum of 2 quarters · filed 2017-10-27
$5.70M
10-Q · filed 2017-10-27
$2.50M
derived: sum of 4 quarters · filed 2019-02-15
2017-06-30$2.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28
$4.10M
10-Q · filed 2017-07-28
$900.00K
derived: sum of 3 quarters · filed 2019-02-15
2017-03-31$2.10M
10-Q · filed 2017-04-28
-$1.10M
derived: sum of 2 quarters · filed 2019-02-15
2016-12-31-$3.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-15
$6.90M
10-K · filed 2019-02-15
2016-09-30$10.10M
10-Q · filed 2016-10-28
2015-12-31$16.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16
$36.60M
derived: sum of 2 quarters · filed 2018-02-16
$55.40M
derived: sum of 3 quarters · filed 2018-02-16
$65.70M
10-K · filed 2018-02-16
2015-09-30$20.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-29
$38.80M
derived: sum of 2 quarters · filed 2015-10-29
$49.10M
10-Q · filed 2015-10-29
$51.00M
derived: sum of 4 quarters · filed 2016-02-19
2015-06-30$18.80M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-29
$29.10M
10-Q · filed 2015-07-29
$31.00M
derived: sum of 3 quarters · filed 2016-02-19
$28.40M
derived: sum of 4 quarters · filed 2016-02-19
2015-03-31$10.30M
10-Q · filed 2015-04-29
$12.20M
derived: sum of 2 quarters · filed 2016-02-19
$9.60M
derived: sum of 3 quarters · filed 2016-02-19
$12.30M
derived: sum of 4 quarters · filed 2016-02-19
2014-12-31$1.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19
-$700.00K
derived: sum of 2 quarters · filed 2016-02-19
$2.00M
derived: sum of 3 quarters · filed 2016-02-19
$7.00M
10-K · filed 2016-02-19
2014-09-30-$2.60M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-31
$100.00K
derived: sum of 2 quarters · filed 2014-10-31
$5.10M
10-Q · filed 2014-10-31
$7.30M
derived: sum of 4 quarters · filed 2016-02-19
2014-06-30$2.70M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-04
$7.70M
10-Q · filed 2014-08-04
$9.90M
derived: sum of 3 quarters · filed 2016-02-19
2014-03-31$5.00M
10-Q · filed 2014-05-02
$7.20M
derived: sum of 2 quarters · filed 2016-02-19
2013-12-31$2.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19
$20.50M
10-K · filed 2016-02-19
2013-09-30$18.30M
10-Q · filed 2013-11-07
2012-12-31$11.30M
10-K · filed 2015-02-20
2011-12-31-$27.70M
10-K · filed 2014-02-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
STERIS plc (STE)Ireland$20.343B25.49
ZIMMER BIOMET HOLDINGS, INC. (ZBH)United States$17.103B20.66
ALIGN TECHNOLOGY INC (ALGN)United States$10.346B29.06
MSA Safety Inc (MSA)United States$7.023B21.47
ESTABLISHMENT LABS HOLDINGS INC. (ESTA)$1.954B-65.76
Cadre Holdings, Inc. (CDRE)United States$1.123B33.88
Enovis CORP (ENOV)United States$1.053B-1.18
Anteris Technologies Global Corp. (AVR)United States$0.746B
Sanara MedTech Inc. (SMTI)United States$0.323B-6.81
Inogen Inc (INGN)United States$0.139B-7.00